-
Mashup Score: 3Belantamab Mafodotin Induces Durable Response When Combined With Pom-Dex, Despite Ocular Effects | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The anti-BCMA belantamab mafodotin (belamaf), plus pomalidomide and dexamethasone (Pd), produced durable responses in patients with relapsed or refractory multiple myeloma (MM), but adverse ocular effects were common though manageable, researchers reported in a new paper in Nature Medicine. The results of the phase I/II ALGONQUIN trial — mainly intended to evaluate dose-limiting toxicities, identify a recommended phase II dose,
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Jill Sederstrom is a journalist based in Kansas City. For decades, health systems across the country have been devoting significant resources to make the shift to electronic health records (EHRs). Patient data are now at our fingertips at a moment’s notice, improving interoperability among providers and making it easier than ever to transfer data to pharmacies, laboratories, billing departments, and insurance companies. The growth in digitized data has also paved the path for new research advancements,
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Validate User - 1 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Daratumumab Effective as Adjunctive Maintenance Therapy for Multiple Myeloma | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) induction and consolidation therapy and to lenalidomide maintenance therapy confers a significant benefit to transplant-eligible patients with newly diagnosed (ND) multiple myeloma (MM). Pieter Sonneveld, MD, PhD, professor of hematology at the Erasmus MC Cancer Institute in the Netherlands, reported the improvement in progression-free
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0ASH Clinical News: April 2024 From the Desk Of... - 1 month(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews the upcoming April 2024 issue of the magazine. Highlights include a feature on patient data and p…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Validate User - 1 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Imetelstat Produces RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The competitive telomerase inhibitor imetelstat produced prolonged independence from red blood cell (RBC) transfusions in a considerable number of patients with lower-risk myelodysplastic syndromes (MDS) who were ineligible for, had relapsed on, or been refractory to erythropoiesis-stimulating agents (ESA), according to new phase III findings published in The Lancet. The results from the IMerge trial point to the prospect of a
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Brea C. Lipe, MD, is a professor of medicine and clinical director of the multiple myeloma program at the James P. Wilmot Cancer Center of the University of Rochester Medical Center in New York. I have always loved the words and stories contained within books. I would even say that my love of books has propelled much of my success in life, serving as an escape, inspiration, reimagination, or education. I make a conscious effort to honor this personal legacy by continued reading and reflecting on stories
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Validate User - 2 month(s) ago
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0ASCO Panel Creates Guidelines for Drug Shortage | ASH Clinical News | American Society of Hematology - 2 month(s) ago
The American Society of Clinical Oncology (ASCO) put together a multidisciplinary panel to provide clinical guidance amid the chemotherapy shortage. The panel is comprised of oncologists, ethicists, and patient advocates and is designed to help providers navigate instances in which rationing therapies or considering alternative therapies is necessary. The 44-person group devised a set of general guiding principles providers can refer to during drug shortages, including subsets for specific disease types.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
Results in @NatureMedicine from the phase I/II #ALGONQUIN trial showed belantamab mafodotin (#belamaf) plus #pomalidomide and #dexamethasone produced durable responses in patients with R/R #MM, but adverse ocular effects were common though manageable. https://t.co/R9vtmfn7Jr https://t.co/gwwOmSPvxP